

**RIGEL (RIGL)**

Treatment with R112 failed to show a statistically significant difference from placebo in improving nasal allergy symptoms.

Rigel Pharmaceuticals (RIGL - [news](#)) announced results from a comparative Phase 2 clinical study of **R112**, a potential intranasal therapy for the treatment of allergic rhinitis. The randomized, double-blind study compared R112 and Beconase AQ(R) (beclomethasone) nasal spray to placebo, over a 7-day period. In the trial, **treatment with R112 failed to show a statistically significant difference from placebo treatment in improving nasal allergy symptoms, the study's primary endpoint.** Beconase AQ was superior to placebo treatment. Rigel will host a conference call today at 4:30 p.m. Eastern to discuss these results (see below for conference call details).

James M. Gower, chairman and chief executive officer of Rigel expressed disappointment and so will be the **shareholders of the stock that seems to sink in the ocean of losses.** As much as he is surprised, those shareholders will be saddened today when they open their eyes and see their stock loses around \$14 before they sip their morning coffee. The surprise came from the fact that earlier Phase 2 'Park' study of R112 demonstrated a statistically significant reduction in the symptoms associated with allergies. These studies had demonstrated that R112 has statistically significant efficacy in improving symptoms of allergic rhinitis, including sneezing, stuffy nose, running nose, itchy nose, itchy throat, post nasal drip, cough, headache and facial pain, and had a rapid onset of action as early as 30-45 minutes over a two day period. In all clinical studies to date, R112 has been shown to have a favorable safety profile.

READ MORE [Rigel Announces Disappointing Results from Phase II Study of R112 for the Treatment of Allergic Rhinitis](#)

PROHOST RESEARCH
P.O. BOX 640 429
Oakland Gardens, NY 11364
Telephone : 516 678 1335
Fax 718 423 2731
E-mail prohost@aol.com.

FORWARD-LOOKING STATEMENT Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: <http://www.sec.gov/consumer/cyberfr.htm>